Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center



Nivolumab with or without Ipilimumab in Treating Patients with Refractory Metastatic Anal Canal Cancer

Rectal

This phase II trial studies how well nivolumab with or without ipilimumab works in treating patients with anal canal cancer that has not responded to previous treatment (refractory) and has spread to other places in the body (metastatic). Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Rectal
II
Ciombor, Kristen
NCT02314169
VICCGI1561ET-CT

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: